This site is intended for healthcare professionals outside the US

×

Clinical Experience

Print |

More Than 12 Million Doses Administered Worldwide1*

Choose more than 20 years of clinical experience1†

Sandostatin® LAR® is the most prescribed and most studied medical therapy in the treatment of acromegaly. Sandostatin® LAR® has a well-established safety profile backed by more than 2 decades of clinical use and more than 1.2 million patient-years of experience.1*†

  • >10,000 published articles2‡
  • >600 clinical trials1‡

*Includes immediate-release Sandostatin® and Sandostatin® LAR® for all approved indications.
†For all approved indications.
‡Combined experience with immediate-release Sandostatin® and Sandostatin® LAR®.

Sandostatin® offers the benefit of 1 type of therapy, available in 2 formulations. Sandostatin® Injection, approved for use since 1987, is a subcutaneous (s.c.) formulation of the drug octreotide acetate.1

Sandostatin® LAR®, the long-acting formulation of this drug, was approved for use globally in 1997 and maintains all of the clinical and pharmacological characteristics of the immediate-release dosage form of s.c. Sandostatin® Injection. Sandostatin® LAR® provides the added feature of convenient, once-monthly administration and has a well-tolerated safety profile backed by more than 2 decades of clinical use.3-5

Did you know? Sandostatin® LAR® works at the site of the tumor to regulate GH secretion and cell growth.6 Learn more.

References:
1. Data on file. Novartis Pharmaceuticals Corp. 2. PubMed. National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/pubmed/?term=octreotide. Accessed April 1, 2019. 3. Sandostatin® LAR® Summary of Product Characteristics. Novartis Pharma AG. 2018. 4. Ayuk J, Sheppard MC. Growth hormone and its disorders. Postgrad Med J. 2006;82(963):24-30. 5. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88(7):3090-3098. 6. Paisley AN, Trainer PJ. Medical treatment in acromegaly. Curr Opin Pharmacol. 2003;3(6):672-677.

Please see the Summary of Product Characteristics.